How AstraZeneca Bilked China’s Insurance Program Out of Millions of Yuan

AstraZeneca Business Innovation Center. Photo: AstraZeneca

China’s investigation into medical insurance fraud allegations at pharmaceutical giant AstraZeneca PLC’s China branch has reached the firm’s highest level of executive — Leon Wang, the division’s president, was confirmed to be under investigation this week.

Following a three-year probe, dozens of current and former AstraZeneca China executives, regional sales heads and pharmaceutical representatives have been investigated, with court files showing that millions of yuan could be involved in the fraud case.

【Subscribe now and save 40% !】